Siltuximab (INN, trade name Sylvant; also known as CNTO 328, anti-IL-6 chimeric monoclonal antibody or cCLB8) is a chimeric (made from human and mouse... 10 KB (852 words) - 17:33, 22 January 2024 |
 | treatment for iMCD is anti-IL-6 therapy with siltuximab (or tocilizumab, if siltuximab is not available). Siltuximab is the only FDA-approved treatment for... 23 KB (2,400 words) - 04:53, 15 April 2024 |
directed against the IL6-receptor. The second, siltuximab (Sylvant), is directed against IL-6 itself. Siltuximab is approved for treatment of human immunodeficiency... 12 KB (1,289 words) - 19:20, 4 December 2023 |
| features of iMCD, and blockade of the IL-6 pathway using the medications siltuximab and tocilizumab effectively treats some patients with iMCD. However, many... 27 KB (3,189 words) - 21:42, 18 August 2023 |
 | Antibodies: ARGX-109 Clazakizumab Elsilimomab mAb 1339 Olokizumab Sarilumab Siltuximab Sirukumab Tocilizumab Levilimab IL-7 Agonists: Interleukin 7 IL-8 See... 22 KB (1,841 words) - 14:41, 23 April 2024 |
Tocilizumab L04AC08 Canakinumab L04AC09 Briakinumab L04AC10 Secukinumab L04AC11 Siltuximab L04AC12 Brodalumab L04AC13 Ixekizumab L04AC14 Sarilumab L04AC15 Sirukumab... 3 KB (367 words) - 15:37, 25 January 2024 |
 | antibody preparation directed against B cells bearing the CD20 antigen, or siltuximab, a monoclonal antibody preparation directed against interleukin-6, may... 25 KB (2,239 words) - 19:32, 23 November 2023 |
Ravulizumab Risankizumab Ritlecitinib Rozanolixizumab Sarilumab Satralizumab Siltuximab Siponimod Sirukumab Spesolimab Sutimlimab Tildrakizumab Tofacitinib Upadacitinib... 7 KB (271 words) - 15:59, 7 February 2024 |
Antibodies: ARGX-109 Clazakizumab Elsilimomab mAb 1339 Olokizumab Sarilumab Siltuximab Sirukumab Tocilizumab Levilimab IL-7 Agonists: Interleukin 7 IL-8 See... 23 KB (1,806 words) - 03:46, 17 April 2024 |
 | Antibodies: ARGX-109 Clazakizumab Elsilimomab mAb 1339 Olokizumab Sarilumab Siltuximab Sirukumab Tocilizumab Levilimab IL-7 Agonists: Interleukin 7 IL-8 See... 15 KB (1,152 words) - 06:14, 7 April 2024 |
 | Loncastuximab tesirine Margetuximab Mirvetuximab soravtansine Rituximab# Siltuximab Ublituximab Zolbetuximab Humanized AbituzumabĀ§ Alemtuzumab Belantamab... 20 KB (1,722 words) - 05:36, 7 April 2024 |
Antibodies: ARGX-109 Clazakizumab Elsilimomab mAb 1339 Olokizumab Sarilumab Siltuximab Sirukumab Tocilizumab Levilimab IL-7 Agonists: Interleukin 7 IL-8 See... 41 KB (3,462 words) - 05:59, 25 April 2024 |
Antibodies: ARGX-109 Clazakizumab Elsilimomab mAb 1339 Olokizumab Sarilumab Siltuximab Sirukumab Tocilizumab Levilimab IL-7 Agonists: Interleukin 7 IL-8 See... 14 KB (1,017 words) - 05:42, 14 April 2024 |
 | Antibodies: ARGX-109 Clazakizumab Elsilimomab mAb 1339 Olokizumab Sarilumab Siltuximab Sirukumab Tocilizumab Levilimab IL-7 Agonists: Interleukin 7 IL-8 See... 64 KB (7,425 words) - 15:13, 9 April 2024 |
 | Antibodies: ARGX-109 Clazakizumab Elsilimomab mAb 1339 Olokizumab Sarilumab Siltuximab Sirukumab Tocilizumab Levilimab IL-7 Agonists: Interleukin 7 IL-8 See... 24 KB (2,070 words) - 07:13, 15 March 2024 |
 | Antibodies: ARGX-109 Clazakizumab Elsilimomab mAb 1339 Olokizumab Sarilumab Siltuximab Sirukumab Tocilizumab Levilimab IL-7 Agonists: Interleukin 7 IL-8 See... 22 KB (2,577 words) - 06:53, 17 April 2024 |
Antibodies: ARGX-109 Clazakizumab Elsilimomab mAb 1339 Olokizumab Sarilumab Siltuximab Sirukumab Tocilizumab Levilimab IL-7 Agonists: Interleukin 7 IL-8 See... 44 KB (4,186 words) - 06:40, 13 March 2024 |
Antibodies: ARGX-109 Clazakizumab Elsilimomab mAb 1339 Olokizumab Sarilumab Siltuximab Sirukumab Tocilizumab Levilimab IL-7 Agonists: Interleukin 7 IL-8 See... 5 KB (267 words) - 03:30, 20 April 2024 |
 | Antibodies: ARGX-109 Clazakizumab Elsilimomab mAb 1339 Olokizumab Sarilumab Siltuximab Sirukumab Tocilizumab Levilimab IL-7 Agonists: Interleukin 7 IL-8 See... 14 KB (1,578 words) - 14:00, 26 February 2024 |
 | Antibodies: ARGX-109 Clazakizumab Elsilimomab mAb 1339 Olokizumab Sarilumab Siltuximab Sirukumab Tocilizumab Levilimab IL-7 Agonists: Interleukin 7 IL-8 See... 49 KB (6,005 words) - 11:09, 8 February 2024 |
 | Antibodies: ARGX-109 Clazakizumab Elsilimomab mAb 1339 Olokizumab Sarilumab Siltuximab Sirukumab Tocilizumab Levilimab IL-7 Agonists: Interleukin 7 IL-8 See... 43 KB (4,986 words) - 09:18, 24 March 2024 |
Antibodies: ARGX-109 Clazakizumab Elsilimomab mAb 1339 Olokizumab Sarilumab Siltuximab Sirukumab Tocilizumab Levilimab IL-7 Agonists: Interleukin 7 IL-8 See... 14 KB (1,145 words) - 06:41, 10 April 2024 |
 | Antibodies: ARGX-109 Clazakizumab Elsilimomab mAb 1339 Olokizumab Sarilumab Siltuximab Sirukumab Tocilizumab Levilimab IL-7 Agonists: Interleukin 7 IL-8 See... 26 KB (3,305 words) - 06:50, 28 March 2024 |
Antibodies: ARGX-109 Clazakizumab Elsilimomab mAb 1339 Olokizumab Sarilumab Siltuximab Sirukumab Tocilizumab Levilimab IL-7 Agonists: Interleukin 7 IL-8 See... 16 KB (1,451 words) - 21:00, 23 April 2024 |
 | Antibodies: ARGX-109 Clazakizumab Elsilimomab mAb 1339 Olokizumab Sarilumab Siltuximab Sirukumab Tocilizumab Levilimab IL-7 Agonists: Interleukin 7 IL-8 See... 19 KB (2,392 words) - 19:50, 26 February 2024 |
Antibodies: ARGX-109 Clazakizumab Elsilimomab mAb 1339 Olokizumab Sarilumab Siltuximab Sirukumab Tocilizumab Levilimab IL-7 Agonists: Interleukin 7 IL-8 See... 17 KB (1,629 words) - 05:29, 7 April 2024 |
 | Antibodies: ARGX-109 Clazakizumab Elsilimomab mAb 1339 Olokizumab Sarilumab Siltuximab Sirukumab Tocilizumab Levilimab IL-7 Agonists: Interleukin 7 IL-8 See... 40 KB (4,858 words) - 15:15, 9 April 2024 |
Antibodies: ARGX-109 Clazakizumab Elsilimomab mAb 1339 Olokizumab Sarilumab Siltuximab Sirukumab Tocilizumab Levilimab IL-7 Agonists: Interleukin 7 IL-8 See... 13 KB (1,478 words) - 06:37, 13 March 2024 |
silperisone (INN) Silphen siltenzepine (INN) silteplase (INN) Siltussin-CF siltuximab (USAN) Silvadene simaldrate (INN) simenepag (USAN, INN) simendan (INN)... 4 KB (261 words) - 16:35, 20 March 2022 |
 | IFN-Ī± systemic lupus erythematosus (SLE), dermatomyositis, polymyositis Siltuximab Sylvant mab chimeric IL-6 Y cancer Simtuzumab mab humanized LOXL2 fibrosis... 133 KB (3,983 words) - 02:16, 19 April 2024 |